Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
RGCC was launched in 2004 by genetics pioneer
Dr. Ioannis Papasotiriou with a view to developing personalized treatment options to treat cancer effectively.
His belief that personalized medicine using the information in a patient’s genes is the way forward lies at the very heart of everything we do.
Our liquid biopsies represent a revolutionary approach to cancer testing and research, offering distinct advantages over traditional tissue biopsies. Minimally invasive and more convenient, liquid biopsies involve a simple blood draw, making them patient-friendly. Moreover, they are cost-effective, enhancing accessibility for patients and healthcare practitioners alike.
Additionally, unlike traditional biopsies that offer insights from one specific location in the body, liquid biopsies capture information from distant (metastatic) sites as well. This means that liquid biopsies paint a complete picture of cancer throughout the patient's body, offering a comprehensive perspective that can be invaluable for precise diagnosis and treatment planning.
At RGCC, we understand that treatment options go beyond traditional chemotherapy. Our tests evaluate the effectiveness of over 50 chemotherapeutic agents alongside natural substances. This holistic approach not only expands treatment options for you to choose from, it also helps identify treatments that work best for you!
Liquid biopsies provide a comprehensive, real-time view of a patient’s cancer status. Frequent testing allows continuous monitoring, facilitating prompt adjustments to treatment plans.
These tests also reveal the genetic composition of the cancer, enabling the identification of highly effective treatments tailored to individual biology. This personalized approach helps you choose treatments that will likely have the greatest chance of showing a positive result for your body and cancer.
Our commitment extends to advancing personalized medicine through relentless research and innovation. Our experts continually strive to develop new diagnostic and therapeutic options for cancer.
Our liquid biopsy tests analyze circulating tumor cells (CTCs) and associated biomarkers in the bloodstream. This provides comprehensive insights into a patient’s cancer, guiding treatment decisions and monitoring disease progression.
Our team is at the forefront of the quest for more personalized and precise cancer treatments. We are globally recognized as the leading center in the field of personalized medicine, developing cutting-edge technologies that can help identify the most effective treatments for each individual patient.
At RGCC, we are committed to providing innovative solutions for cancer and chronic diseases. Our global mission is to help patients across the world have access to the latest diagnostic and therapeutic options for their conditions.
Our state-of-the-art laboratory facilities in Europe are equipped with the latest technology and staffed by world-class experts.
Our scientists are dedicated to pioneering research that propels the field of personalized medicine forward. We use innovative techniques to provide timely and precise information so patients and their practitioners can take therapeutic action based on results that provide granular levels of detail about their condition.
At RGCC, we envision a future where cancer treatment is truly personalized and targeted to meet each patient’s unique needs. Through our research and innovation, we work tirelessly to turn this vision into reality, offering renewed hope to patients and their families worldwide.
Excellence is at the core of everything we do at RGCC, from the quality of our tests and protocols to the support we provide to patients and practitioners. Whether you’re a patient seeking hope or a healthcare professional dedicated to improving patient outcomes, we welcome the opportunity to collaborate and provide personalized solutions that make a real difference.
